EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE

被引：0
|
作者：
Zackova, D. [1 ]
Klamova, H. [3 ]
Doubek, M. [1 ]
Pospisil, Z. [2 ]
Dvorakova, D. [1 ]
Jurcek, T. [1 ]
Moravcova, J. [3 ]
Machova, K. [3 ]
Rulcova, J. [3 ]
Dobesova, B. [1 ]
Rysava, J. [3 ]
Cetkovsky, P. [3 ]
Razga, F. [1 ]
Mayer, J. [1 ]
机构：
[1] Univ Hosp, Dept Internal Med & Hematooncol, Brno, Czech Republic
[2] Masaryk Univ, Dept Math & Stat, Brno, Czech Republic
[3] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0858
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [11] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [12] EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    D'Adda, M.
    Stagno, F.
    Levato, L.
    Carella, A. M.
    Martino, B.
    Tiribelli, M.
    Rege-Cambrin, G.
    Gozzini, A.
    Salvucci, M.
    Cedrone, M.
    Trabacchi, E.
    Usala, E.
    Scortechini, A. R.
    Luciano, L.
    Soverini, S.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2016, 101 : 62 - 62
  • [13] EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    D'Adda, M.
    Stagno, F.
    Levato, L.
    Carella, A. M.
    Martino, B.
    Tiribelli, M.
    Rege-Cambrin, G.
    Gozzini, A.
    Salvucci, M.
    Cedrone, M.
    Trabacchi, E.
    Usala, E.
    Scortechini, A. R.
    Luciano, L.
    Soverini, S.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2016, 101 : S102 - S102
  • [14] Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
    Shin, Hyejin
    Choi, Soo Young
    Kee, Kyung-Mi
    Kim, Soo-Hyun
    Yang, Seon-Young
    Jung, Su Young
    Noh, Hayeon
    Zang, Dae Young
    Kim, Dong-Wook
    Lee, Jangik, I
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 417 - 426
  • [15] Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
    Hyejin Shin
    Soo Young Choi
    Kyung-Mi Kee
    Soo-Hyun Kim
    Seon-Young Yang
    Su Young Jung
    Hayeon Noh
    Dae Young Zang
    Dong-Wook Kim
    Jangik I. Lee
    International Journal of Hematology, 2020, 111 : 417 - 426
  • [16] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML)
    Brummendorf, T.
    Cortes, J.
    Turkina, A.
    Masszi, T.
    Assouline, S.
    Durrant, S.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 468 - 468
  • [18] Elimination of chronic myeloid leukemia (CML) cells with a novel photodynamic treatment.
    Roy, DC
    Paquette, Y
    Balassy, A
    Villeneuve, L
    Beauger, N
    Blanchard, L
    Giorgi, O
    Gladu, I
    Hamel, R
    Perreault, C
    Molfino, N
    BLOOD, 1999, 94 (10) : 144A - 144A
  • [19] Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Gozzini, Antonella
    Usala, Emilio
    Carella, Angelo M.
    Rege-Cambrin, Giovanna
    Martino, Bruno
    Abruzzese, Elisabetta
    Albano, Francesco
    Stagno, Fabio
    Luciano, Luigia
    D'Adda, Mariella
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Lunghi, Monia
    Falcone, Antonietta Pia
    Musolino, Caterina
    Levato, Luciano
    Venturi, Claudia
    Soverini, Simona
    Cavo, Michele
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 617 - 622
  • [20] Imatinib mesylate as first line therapy in patients with Chronic Myeloid Leukemia (CML) - An experience from eastern India
    Dey, S.
    Mukhopadhyay, S.
    Gorai, K.
    Paul, C.
    Gupta, P.
    Choudhury, R.
    Ahmed, R.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 51 - 52
12345